Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Accumulated Expenses (2018 - 2023)

Avai Bio's Accumulated Expenses history spans 6 years, with the latest figure at $410000.0 for Q3 2023.

  • On a quarterly basis, Accumulated Expenses rose 157.05% to $410000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $410000.0, a 157.05% increase, with the full-year FY2023 number at $192600.0, up 0.84% from a year prior.
  • Accumulated Expenses hit $410000.0 in Q3 2023 for Avai Bio, down from $458600.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for AVAI hit a ceiling of $458600.0 in Q2 2023 and a floor of $1143.0 in Q4 2020.
  • Historically, Accumulated Expenses has averaged $140346.9 across 5 years, with a median of $74155.0 in 2019.
  • Biggest five-year swings in Accumulated Expenses: tumbled 99.48% in 2020 and later surged 9099.6% in 2023.
  • Tracing AVAI's Accumulated Expenses over 5 years: stood at $219795.0 in 2019, then tumbled by 99.48% to $1143.0 in 2020, then skyrocketed by 6247.68% to $72554.0 in 2021, then tumbled by 86.09% to $10092.0 in 2022, then surged by 3962.62% to $410000.0 in 2023.
  • Business Quant data shows Accumulated Expenses for AVAI at $410000.0 in Q3 2023, $458600.0 in Q2 2023, and $192600.0 in Q1 2023.